Diopter Technologies has reached a significant milestone with the completion of early clinical studies for its dissolving amniotic membrane and biopolymer contact lens, a pioneering therapeutic device aimed at treating various ocular surface diseases. This innovative lens is designed to address conditions such as dry eye syndrome, corneal trauma injuries, and post-surgical wounds by releasing growth factors from amniotic-derived materials and dissolving within 48-72 hours, thereby eliminating the need for clinical removal.

The technology behind this device is notable for several key features. It provides sustained growth factor release, utilizing amniotic membrane components known to reduce scarring and inflammation while promoting epithelial regeneration. The self-dissolving design of the biopolymer matrix ensures complete dissolution within 2-3 days, avoiding the risks associated with removal procedures that could disrupt healing tissues. Additionally, the device enhances bioavailability by delivering growth factors to the ocular surface in a synergistic manner, combining the benefits of both the amnion and co-polymer.

Initial clinical study results have been promising, with no reports of adverse events and an observed increase in patient comfort over a 48-hour continuous wear period compared to standard silicon hydrogel lenses. Chris Adams, CEO of Diopter Technologies, highlighted the device’s ability to actively deliver healing factors to the eye, marking a shift from passive protection to intelligent tissue remodeling in ocular surface rehabilitation.

The device is currently under clinical study for multiple indications, including chemical/thermal injury recovery, post-refractive surgery care, and chronic dry eye management, with preliminary data indicating potential in addressing these billion-dollar market opportunities. Diopter Technologies plans to launch the product in Q1 2026, following the completion of ongoing human trials and submission of an FDA 510K application. This development represents a strategic expansion of the company’s ocular drug delivery portfolio, building on its previous achievements in the field.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Diopter Technologies Completes Early Clinical Study for Innovative Ocular Surface Disease Treatment.